Dr. Reddy's Srikakulam facility receives 3 U.S. FDA observations
Summary
- The U.S. FDA conducted a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at Dr. Reddy's FTO-SEZ Process Unit-02 in Srikakulam.
- The inspection resulted in 3 observations being issued by the U.S. FDA.
- The observations are related to the facility's compliance with U.S. FDA regulations and standards.
Key Facts
- · Dr. Reddy's is a pharmaceutical company
- · The inspection was conducted at the Srikakulam facility
- · 3 observations were issued by the U.S. FDA
- · The observations are related to GMP and PAI
Why it matters
The U.S. FDA observations can impact Dr. Reddy's ability to export pharmaceutical products to the United States, affecting the company's revenue and reputation.
#Pharmaceuticals#U.S. FDA#Dr. Reddy's#GMP#PAI